title: Buprenorphine-naloxone maintenance following release from jail.
abstract: Primary care is understudied as a reentry drug and alcohol treatment setting. This study compared treatment retention and opioid misuse among opioid-dependent adults seeking buprenorphine/naloxone maintenance in an urban primary care clinic following release from jail versus community referrals. Postrelease patients were either (a) induced to buprenorphine in-jail as part of a clinical trial, or (b) seeking buprenorphine induction post release. From 2007 to 2008, N = 142 patients were new to primary care buprenorphine: n = 32 postrelease; n = 110 induced after community referral and without recent incarceration. Jail-released patients were more likely African American or Hispanic and uninsured. Treatment retention rates for postrelease (37%) versus community (30%) referrals were similar at 48 weeks. Rates of opioid positive urines and self-reported opioid misuse were also similar between groups. Postrelease patients in primary care buprenorphine treatment had equal treatment retention and rates of opioid abstinence versus community-referred patients.
authors.affiliation: Division of General Internal Medicine, New York University School of Medicine, New York, New York, USA. joshua.lee@med.nyu.edu
authors.forename: Joshua D
authors.initials: JD
authors.lastname: Lee
authors.forename: Ellie
authors.initials: E
authors.lastname: Grossman
authors.forename: Andrea
authors.initials: A
authors.lastname: Truncali
authors.forename: John
authors.initials: J
authors.lastname: Rotrosen
authors.forename: Andrew
authors.initials: A
authors.lastname: Rosenblum
authors.forename: Stephen
authors.initials: S
authors.lastname: Magura
authors.forename: Marc N
authors.initials: MN
authors.lastname: Gourevitch
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000627:therapeutic use*; D002047:Buprenorphine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D009519:New York City; D009293:Opioid-Related Disorders / Q000188:drug therapy*; D011320:Primary Health Care; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D009270:Naloxone; D002047:Buprenorphine